Equities Analysts Set Expectations for argenx Q4 Earnings

argenx SE (NASDAQ:ARGX) – Equities researchers at Wedbush raised their Q4 2024 earnings estimates for shares of argenx in a report issued on Monday, January 13th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of $2.74 for the quarter, up from their previous forecast of $1.09. Wedbush has a “Outperform” rating and a $655.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx’s Q1 2025 earnings at $3.11 EPS, Q2 2025 earnings at $4.15 EPS, Q3 2025 earnings at $5.12 EPS, Q4 2025 earnings at $5.95 EPS, FY2025 earnings at $18.37 EPS, FY2026 earnings at $33.33 EPS and FY2027 earnings at $43.65 EPS.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. During the same period in the prior year, the company posted ($1.25) EPS.

Other research analysts have also issued research reports about the stock. William Blair upgraded shares of argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Robert W. Baird cut argenx from an “outperform” rating to a “neutral” rating and raised their target price for the company from $515.00 to $650.00 in a research note on Friday, November 1st. Guggenheim upped their price target on shares of argenx from $585.00 to $665.00 and gave the company a “buy” rating in a report on Friday, November 1st. Deutsche Bank Aktiengesellschaft lowered shares of argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. Finally, Truist Financial reiterated a “buy” rating and set a $700.00 price objective (up previously from $660.00) on shares of argenx in a research report on Tuesday. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, argenx has an average rating of “Moderate Buy” and an average price target of $658.39.

argenx Stock Performance

NASDAQ:ARGX opened at $665.19 on Thursday. The stock has a market cap of $40.16 billion, a price-to-earnings ratio of -755.90 and a beta of 0.59. argenx has a 1 year low of $349.86 and a 1 year high of $678.21. The business has a fifty day moving average of $617.93 and a 200-day moving average of $553.49.

Institutional Trading of argenx

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Cromwell Holdings LLC boosted its stake in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after buying an additional 66 shares in the last quarter. GAMMA Investing LLC grew its stake in argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after buying an additional 56 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of argenx in the second quarter valued at approximately $76,000. Fulton Bank N.A. acquired a new stake in argenx during the 4th quarter valued at $226,000. Finally, Blue Trust Inc. boosted its stake in argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock worth $201,000 after purchasing an additional 298 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.